Fractyl Health reports Q3 EPS (71c), consensus (32c)

As of September 30, 2025, Fractyl had approximately $77.7M in cash and cash equivalents. Based on current business plans, the company believes its cash position will fund operations into early 2027. “The third quarter marked a major inflection point for Fractyl,” said Harith Rajagopalan, co-founder and CEO of Fractyl Health (GUTS). “With positive randomized data from our Revita program showing that durable, drug-free weight maintenance may be attainable, we are pushing the boundaries of what is possible in metabolic disease. We aim to move beyond chronic management and toward durable remission, potentially transforming care for the hundreds of millions of people living with obesity and T2D. With pivotal Revita data and our first-in-human Rejuva study ahead, we believe Fractyl is well positioned for a series of meaningful catalysts that could reshape the future of metabolic medicine.”